Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

NCT06258642 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Recurrent

Interventions

DRUG: Irinotecan Liposome
DRUG: Anlotinib

Sponsor

Fudan University